7 papers in the library · 745 citations · publishing 1994-2026
JAMA Psychiatry March 18, 2026 James I. Hudson, Harrison G. Pope 1 citation
Can a guided psychedelic experience with psilocybin successfully treat refractory depression? In other words, setting aside any simple direct biological drug effect, can psychedelic-assisted psychotherapy1 alleviate suffering via what William James would call a mystical experience?2
Psychedelic medicine (New Rochelle, N.Y.) March 1, 2024 Brian S. Barnett, Miranda Arakelian, David Beebe et al. 28 citations
Psilocybin, a classic hallucinogen, may eventually be approved by the United States Food and Drug Administration for treatment-resistant depression. However, we are aware of only one published national survey of American psychiatrists regarding their opinions about hallucinogens and hallucinogen-assisted therapy, conducted by our group in 2016. Here, we report a repeat survey, using virtually...
The Journal of Nervous and Mental Disease May 17, 2018 Brian S. Barnett, Willie O. Siu, Harrison G. Pope 114 citations
Recent years have seen renewed interest and research about the use of hallucinogens as possible agents in the treatment of psychiatric disorders. However, we are unaware of studies assessing the current attitudes of American psychiatrists regarding hallucinogens. Therefore, we e-mailed surveys to 1000 members of the American Psychiatric Association-250 resident-fellows and 750 attending...
Neurology June 26, 2006 R. Andrew Sewell, John H. Halpern, Harrison G. Pope 259 citations
The authors interviewed 53 cluster headache patients who had used psilocybin or lysergic acid diethylamide (LSD) to treat their condition. Twenty-two of 26 psilocybin users reported that psilocybin aborted attacks; 25 of 48 psilocybin users and 7 of 8 LSD users reported cluster period termination; 18 of 19 psilocybin users and 4 of 5 LSD users reported remission period extension. Research on...
Biological Psychiatry October 15, 2005 John H. Halpern, Andrea R Sherwood, James I. Hudson et al. 186 citations
Hallucinogens are widely used, both by drug abusers and by peoples of traditional cultures who ingest these substances for religious or healing purposes. However, the long-term residual psychological and cognitive effects of hallucinogens remain poorly understood. We recruited three groups of Navajo Native Americans, age 18-45: 1) 61 Native American Church members who regularly ingested peyote,...
American Journal of Psychiatry July 1, 2000 Robert Klitzman, Harrison G. Pope, James I. Hudson 132 citations
OBJECTIVE: The authors explored the association between abuse of 3,4-methylenedioxymethamphetamine (MDMA, or “Ecstasy”) and high-risk sexual behaviors among gay and bisexual men. METHOD: An anonymous questionnaire was completed by 169 gay and bisexual men at three New York City dance clubs. The questionnaire covered demographic indices, use of MDMA and other drugs, and history of high-risk...
American Journal on Addictions 1994 Amanda J. Gruber, Harrison G. Pope 25 citations
Although “cannabis‐induced delusional disorder” is recognized in DSM‐III‐R and appears as “cannabis psychotic disorder” in the draft criteria for DSM‐IV, little information on this entity is available. The authors reviewed available studies of psychiatric syndromes attributed to cannabis use and then surveyed 9,432 admissions at two psychiatric centers, seeking cases of cannabis‐induced...